Sierra Oncology (NASDAQ: SRRA) has appointed Stephen Dilly to serve as its president and CEO starting June. 1. He is also joining the Vancouver, BC-based company’s board of directors. Dilly retired as CEO of Aimmune Therapeutics (NASDAQ: AIMT) in 2018. His…
The company said its representatives may not be able to provide support to certain clinics administering the therapy as physicians and patients take precautions to avoid exposure to the virus. The virus outbreak, which originated in Wuhan, China late last year, has infected more than 1,500 Americans and claimed over 60 lives, prompting health agencies to urge people to practice social distancing. The coronavirus outbreak has also affected other companies with new drugs on the market including Amarin Corp Plc, which suspended in-person interactions for its sales representatives until March 30.
Q4 2019 Aimmune Therapeutics Inc Earnings Call
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
The latest analyst coverage could presage a bad day for Aimmune Therapeutics, Inc. (NASDAQ:AIMT), with the analysts...
The FDA recently approved AIMT's Palforzia as first ever treatment for peanut allergies, but for now, DBVT's Viaskin might only be months behind.It is difficult to make an apples-to-apples comparison between the efficacy of Palforzia v. Viaskin, but I explain…
AIMT earnings call for the period ending March 31, 2020.
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
Q1 2020 Aimmune Therapeutics Inc Earnings Call
Bad Week Gets Worse as Morning Rally Falters
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 10.44% and -67.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) a…
Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
AIMT earnings call for the period ending March 31, 2020.
From social distancing for patients to company representatives meeting with allergists and payers, the rollout of the drug is anything but normal.
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
Investors who take an interest in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) should definitely note that the Independent...
A stem cell biologist, a gene editing expert, and a data engineer walk into a room…and that’s just a few of the people Daphne Koller has recruited in the past two years to Insitro. The South San Francisco-based startup has grand plans to reevaluate and, po…
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why.
Today we provide an in-depth look on Aimmune Therapeutics.The company is focused on targeting food allergies and recently received its first FDA approval.An investment analysis and a preferred investment strategy follow in the paragraphs below.
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. Merck ...
The US stock market may look more attractive than it was before the pandemic.Capital inflows from emerging markets and monetary actions create a positive outlook.Responses to new challenges will determine long-term prospects.Though we expect a correction in t…
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate ...
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights